Thermo Fisher Scientific IL-28A Polyclonal Antibody, Biotin, PeproTech

Applications

Product Specifications

Product Specific Information

Amino Acid Sequence of Recombinant Protein:
PVARLHGALP DARGCHIAQF KSLSPQELQA FKRAKDALEE SLLLKDCRCH SRLFPRTWDL RQLQVRERPM ALEAELALTL KVLEATADTD PALVDVLDQP LHTLHHILSQ FRACIQPQPT AGPRTRGRLH HWLYRLQEAP KKESPGCLEA SVTFNLFRLL TRDLNCVASG DLCV.

Preparation:
Produced from sera of rabbits immunized with highly pure Recombinant Human IFN-lambda2. Anti-Human IFN-lambda2-specific antibody was purified by affinity chromatography and then biotinylated.

Sandwich ELISA:
To detect Human IFN-lambda2 by sandwich ELISA (using 100 µL/well antibody solution), a concentration of 0.25–1.0 µg/mL of this antibody is required.
This biotinylated polyclonal antibody, in conjunction with PeproTech Polyclonal Anti-Human IFN-lambda2 (500-P247) as a capture antibody, allows detection of at least 0.2–0.4 ng/well of Recombinant Human IFN-lambda2.

Western Blot:
To detect Human IFN-lambda2 by Western Blot analysis, use at 0.1–0.2 µg/mL.
When used with compatible secondary reagents, detection limit for Recombinant Human IFN-lambda2 is 1.5–3.0 ng/lane, under either reducing or non-reducing conditions.

Package:
500-P247BT-1MG is provided as 2 × 500 µg.

Target Information

IL-28A belongs to the IFN lambda family, a novel cytokine family within the IL-10 superfamily.
Members include IL-29 (IFN lambda 1), IL-28A (IFN lambda 2), and IL-28B (IFN lambda 3), also known as type III Interferons.
The IFN lambdas signal through a heterodimeric receptor comprising IL-10R2 (shared with other IL-10 family members) and IFN lambda R1 (IL-28R alpha), which is unique to IFN lambdas.
Signaling occurs via the Jak/STAT pathway, similar to type I IFN (IFN alpha/beta), activating many of the same genes despite low sequence homology.
Both IFN families display antiviral activity through induction of antiviral proteins and upregulation of MHC class I expression.
They also exhibit antiproliferative and antitumor effects, suggesting potential use as alternatives to IFN alpha in cancer therapy.
Unlike type I IFNs, which stimulate most cells, response to IFN lambda is limited to dendritic and some tumor cells due to restricted IFN lambda R1 expression.
Additionally, IFN lambda stimulation drives dendritic cells toward producing CD4⁺CD25⁺FoxP3⁺ regulatory T cells, indicating a possible immunoregulatory role.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.